Search

Search Constraints

You searched for: Subject 616.994005 Issue Volume 13(2021)

Search Results

4. A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). (January 2021)

5. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). (February 2021)

6. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. (March 2021)

7. Adverse events induced by nivolumab and ipilimumab combination regimens. (November 2021)

8. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. (May 2021)

9. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. (March 2021)

10. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. (September 2021)